Should You Buy Context Therapeutics Inc (CNTX) Stock After it Has Gained 12.26% in a Week?

The market has been neutral on Context Therapeutics Inc (CNTX) stock recently. CNTX gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Context Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on CNTX!

See Full CNTX Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CNTX Stock Today?

Context Therapeutics Inc (CNTX) stock is trading at $1.19 as of 10:42 AM on Wednesday, Nov 1, a rise of $0.13, or 12.25% from the previous closing price of $1.06. The stock has traded between $1.12 and $1.21 so far today. Volume today is light. So far 22,420 shares have traded compared to average volume of 50,999 shares. To screen for more stocks like Context Therapeutics Inc click here.

More About Context Therapeutics Inc

Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. Click Here to get the full Stock Report for Context Therapeutics Inc stock.